Vytorin Suits Continue

The results of a study that found the Merck & Co. and Schering-Plough Corp. cholesterol drug Vytorin to be no more effective than its generic competitors have prompted attorneys to file a wave of lawsuits on behalf of patients who took the drug. Plaintiffs allege that Merck and Schering-Plough committed consumer fraud by marketing the drug as a more effective treatment to reduce the risk of heart attack. A spokeswoman for Schering-Plough defended Vytorin's effectiveness, saying the company would vigorously defend the claims against them. Peter Page, Law.com 01/28/2008
Read Article